𩺠å
§ç§å°ç§èåç
1ïžâ£ 2014-2016 W Africa Ebola Lessons
- 28,000+ cases, 11,000+ deaths
- Liberia, Sierra Leone, Guinea
- HCW deaths 511 (7% of cases)
- Mass response â international collaboration
- Lessons: ring vaccination effective; mAbs developed; community engagement critical; safe burial practices essential
2ïžâ£ Ervebo Ring Vaccination
- Strategy: vaccinate contacts + contacts of contacts (4° network)
- Single dose effective rapidly
- 100% efficacy in 2015 trial
- Deployed in 2018-2020 DRC + subsequent outbreaks
- WHO stockpile
3ïžâ£ PALM Trial 2019
- Tested 4 therapeutics: ZMapp, remdesivir, REGN-EB3, mAb114
- REGN-EB3 + mAb114 superior (35.1% + 33.5% mortality)
- ZMapp + remdesivir less effective (49.7% + 53.1%)
- mAbs became standard of care
4ïžâ£ Returning Traveler Workup
- Fever within 21 days of return from outbreak area
- Immediate isolation
- Notify Public Health
- Specialized assessment + transport
- Travel hx essential
- Differential: malaria first (treatable), then filovirus
5ïžâ£ 2024 Rwanda Marburg Outbreak
- August 2024 onset
- 50+ cases, mortality ~ 30% (lower than historical Marburg)
- HCWs primarily affected
- Vaccine emergency rollout: cAd3-Marburg + rVSV-MARV Phase 2 trials
- Treatment: supportive + investigational mAbs (MBP091)
- WHO + CDC coordination
6ïžâ£ Sexual Transmission Survivor Counseling
- Male survivors: viable virus in semen weeks-months
- WHO recommends abstinence or condom use up to 12 months post-recovery
- Monthly testing to confirm clearance
- Female survivors: lower but possible risk
- Reproductive counseling
7ïžâ£ Post-Ebola Syndrome Management
- Multi-disciplinary follow-up
- Ophthalmology (uveitis common; recurrent)
- Audiology
- Rheumatology (arthralgia)
- Mental health (PTSD, anxiety, depression common)
- Reintegration into community
- Survivor stigma
8ïžâ£ å¥ä¿ / Taiwan
- éå ± mandatory
- Isolation + specialist consult
- è¡çå± emergency response
- Taiwan: no local cases historically; awareness for returning travelers
9ïžâ£ Future Vaccines + Therapeutics
- Pan-filovirus vaccines
- Sudan-specific vaccines (2022 Uganda outbreak gap)
- mRNA Ebola vaccine candidates
- Improved mAb cocktails
- Antiviral combinations
10. Bioterror Considerations
- Filoviruses Category A bioterror potential
- BSL-4 lab considerations
- Stockpile + readiness
- Surveillance + early detection